arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

AtriCure, Inc.

ATRC
$41.41 ▲ +1.91 (+4.82%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
18 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
40
Health
Weak
Neutral
auto_awesome

Analytical Summary

AtriCure, Inc. demonstrates solid fundamentals with strength in Debt to Equity. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $2.0B
Dividend Yield
Revenue Growth 14.9%
Op. Margin -1.8%
ROIC -1.9%
FCF / Share $1.01
Trailing P/E
Price / Book 4.2x
FCF Yield 2.4%
Debt / Equity 0.13
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$534.53M
↑ +14.9%
Net Income Profit after all expenses
$-11.45M
↑ +74.4%
Operating Margin Operating profit as % of sales
-1.8%
↑ +79.4% 25th
FCF / Share Free cash flow per share
$1.01
↑ +6274.5%
Long-Term Debt Long-term obligations
$61.87M
— 0.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
37
Returns
41
Financial Health
61
Cash Quality
4

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 68 quarters